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Abstract
Background: Developing novel drugs from traditional medicinal knowledge can serve as a means to improve
public health. Yet countries in sub-Saharan Africa face barriers in translating traditional medicinal knowledge into
commercially viable health products. Barriers in moving along the road towards making a new drug available
include insufficient manufacturing capacity; knowledge sharing between scientists and medical healers; regulatory
hurdles; quality control issues; pricing and distribution; and lack of financing. The case study method was used to
illustrate efforts to overcome these barriers during the development in Nigeria of Niprisan – a novel drug for the
treatment of sickle cell anemia, a chronic blood disorder with few effective therapies.
Discussion: Building on the knowledge of a traditional medicine practitioner, Nigeria’s National Institute for
Pharmaceutical Research and Development (NIPRD) developed the traditional herbal medicine Niprisan. The
commercialization of Niprisan reached a number of commercial milestones, including regulatory approval in
Nigeria; securing US-based commercial partner XeChem; demonstrating clinical efficacy and safety; being awarded
orphan drug status by the US Food and Drug Administration; and striking important relationships with domestic
and international groups. Despite these successes, however, XeChem did not achieve mainstream success for
Niprisan in Nigeria or in the United States. A number of reasons, including inconsistent funding and manufacturing
and management challenges, have been put forth to explain Niprisan’s commercial demise. As of this writing,
NIPRD is considering options for another commercial partner to take the drug forward.
Summary: Evidence from the Niprisan experience suggests that establishing benefit-sharing agreements, fostering
partnerships with established research institutions, improving standardization and quality control, ensuring financial
and managerial due diligence, and recruiting entrepreneurial leaders capable of holding dual scientific and
business responsibilities should be incorporated into future drug development initiatives based on traditional
medicines. Country-level supporting policies and conditions are also important. With more experience and support,
and an improved environment for innovation, developing new drugs from traditional medicines may be an
attractive approach to addressing diseases in sub-Saharan Africa and other regions.
Background
Bringing medicines to market for diseases that affect
public health can be a challenging task, especially in
developing countries where the local environment for
innovation contains challenges that include technical
capacity, financing, and entrepreneurship [1]. But pro-
moting health innovation in developing countries
offers opportunities for these nations to tackle endemic
public health issues, and such endeavors have the
potential to create a reliable stream of affordable medi-
cines for local diseases [2,3]. (See the introductory
paper in this BMC series for further discussion of the
innovation context.)
In countries such as China and India, traditional her-
bal medicines have an important role in public health,
as these medicines are frequently used as a first line of
therapy for meeting the health needs of the population
[4-8]. This role is attributed to the widespread accep-
tance of traditional medicine, its strong link to cultural
beliefs, affordability, and confidence in traditional medi-
cine practitioners [8-13]. Given the innovative potential
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class therapies, the governments of countries like China
have established innovation policies that aim to build
capacity in their commercialization [7].
Similar to Asian countries, the prevalent use of indi-
genous traditional medicines in Africa has prompted a
number of sub-Saharan African nations to establish
research institutes aimed at the study of traditional
medicines [12-15]. (For further discussion on country-
specific use of traditional medicines, see the country
papers in this BMC series.) Yet, pursuing commercial
development to capitalize on indigenous knowledge of
traditional medicines in sub-Saharan Africa faces a
number of challenges, including difficulty in building
knowledge-sharing partnerships between conventional
scientists and traditional medical healers; overcoming
problems with quality control; accurately characterizing
raw materials; financing; and a lack of appetite for high-
risk biotechnology ventures [1-3,16]. Addressing these
barriers is pertinent for supporting commercialization,
as is identifying policy interventions that could ensure
the mobilization of sub-Saharan Africa’s pharmaceutical
potential. This paper illustrates efforts to overcome
these barriers in the development of Niprisan in Nigeria
– a novel drug for the treatment of sickle cell anemia
[17,18].
We used a case study design. We conducted inter-
views with informed consent of key personnel of NIPRD
and Xechem International (Xechem) between 2007 and
2009, including senior directors at NIPRD and the then-
CEO of Xechem. Literature analysis sources included
background documents on Niprisan, related articles
from peer-reviewed literature, news reports, books,
financial filings, web sites, and relevant reports from the
World Health Organization and other groups. Represen-
tatives of NIPRD and Xechem were asked to fact-check
the case study; the analysis and interpretation is our
own. All quotes are from the interviews unless noted,
and with permission. This study was approved by the
Office of Research Ethics of the University of Toronto.
In this article, we chronicle the development of Nipri-
san. We begin by describing how Niprisan was discov-
ered, proceed to discuss the partnerships and
commercial strategy undertaken, and note achievements
and shortcomings with a view to distilling lessons for
the commercialization of medicines in sub-Saharan
Africa.
Discussion
The discovery of Niprisan
Sickle cell anemia, a genetic condition that primarily
affects those of African ancestry, significantly reduces
the patient’s quality of life and productivity; the condi-
tion causes episodes of pain that can last for hours or
days at time [17-20]. The disease interferes with the
body’s oxygen transfer process, and can lead to the for-
mation of small blood clots, which over time deprive
organs and tissues of oxygen. Nigeria is home to the lar-
gest population of sickle cell anemia patients, estimated
to be in excess of 4 million patients with more than 150
000 children born annually with the disease [19]. The
condition is also incident in the African diaspora popu-
lation in North America and Europe.
Despite decades of research, only one FDA approved
drug, hydroxyurea, is available for use in sickle cell ane-
mia [18]. This chemotherapeutic agent stimulates
healthy production of fetal hemoglobin to counteract
the sickling process [18]. Although long-term clinical
studies have shown the drug to improve survival, con-
cerns over genotoxicity and carcinogenesis remain
[17,18].
In the late 1980s, in an effort to advance research of
traditional herbal medicines, Nigeria’s Ministry of
Science and Technology established the NIPRD – a
research body dedicated to identifying, characterizing,
developing, and documenting the use of traditional her-
bal medicines in Nigeria. Despite the frequent use of
traditional medical healers by Nigeria’s populace, tap-
ping into their knowledge remained a challenge, due to
a prevalent lack of trust between conventional scientists
and traditional medical healers and concerns over bio-
piracy [11,13].
In order to overcome this barrier and build an ade-
quate pipeline of traditional herbal medicines, NIPRD
implemented benefit-sharing agreements with traditional
herbal healers – a measure that was seen by Dr. Charles
Wambebe, the first director of NIPRD, to be necessary
for brokering trust and gaining access to a vast pool of
traditional medical knowledge [21]. The agreements for-
mally involved the traditional practitioner in the devel-
opment program, and entitled them to royalties on the
sale of any commercial product developed with their
proprietary knowledge [21]. In exchange, NIPRD was to
receive all necessary information pertaining to the tradi-
tional herbal medicine, including its medicinal use,
method of collection, and method of manufacture [21].
Niprisan was brought to the attention of NIPRD by a
local reverend, Paul Ogunyale, in 1992. The Reverend,
w h oa l s oh o l d sm a s t e r ’s degree, claimed to be using
Niprisan to treat members of his congregation for sickle
cell anemia. NIPRD signed a formal benefit-sharing
agreement with Reverend Ogunyale, which entitled him
and his family to future royalties on Niprisan in
exchange for the recipe of Niprisan and disclosure of all
trade secrets [21]. Preliminary testing and experimenta-
tion by NIPRD researchers and Paul Ogunyale identified
several raw materials thought to be responsible for the
beneficial effect; these sources included Piper guineenses
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fruit, and Sorghum bicolor leaves [22,23].
According to Dr. Wambebe, the agreement with
Reverend Ogunyale and NIPRD was considered to be
the first benefit sharing arrangement of its kind in
Nigeria.
Partnering with the Children’s Hospital of Philadelphia
In 1997, the scientists at NIPRD sent samples of Nipri-
san to Dr. Toshio Asakura of the Children’s Hospital of
Philadelphia. Dr. Asakura, ane x p e r ti ns i c k l ec e l la n e -
mia disorders, conducted animal studies to test the effi-
cacy of Niprisan [24-27]. The results of his work
demonstrated both in transgenic mice and in patient
samples with sickle cell disease that Niprisan did have
potential anti-sickling properties [24-27].
In addition to the findings by Dr. Asakura’sg r o u p ,
NIPRD conducted clinical studies to determine Nipri-
san’s efficacy in patients with sickle cell anemia. Find-
ings from these studies conducted at hospitals in
Nigeria showed that the drug significantly reduced the
number of vaso-occlusive crises [25-27]. The clinical
studies conducted by NIPRD also reported that Niprisan
had an extremely low toxicity profile, unlike other drugs
that have been developed for sickle cell anemia [25-27].
NIPRD’s research efforts resulted in a United States
patent being filed in 1998 entitled: Piper guineense, Pter-
ocarpus osun, Eugenia caryophyllata, and Sorghum bico-
lor extracts for treating sickle cell disease [23].
Partnering with Xechem International (Xechem)
According to scientists at NIPRD, finding a commercial
partner in Nigeria to scale up and manufacture Niprisan
proved difficult as the local pharmaceutical industry in
Nigeria has traditionally focused on marketing and dis-
tribution, with limited capacity in formulation and
development. According to Dr. Inyang, currently the
Director General of NIPRD: “The local drug industry is
not geared towards natural product manufacturing.
They only produce imported generics. At the time,
nobody had the facilities to produce Niprisan. As a
result, I guess they [private sector] saw it as a very
expensive investment with a lot of uncertainty...”
After approaching several pharmaceutical firms in
Nigeria including Emzor Pharmaceuticals – one of
Nigeria’s leading pharmaceutical manufacturers – the
challenge of finding a partner with commercial interest
and facilities remained. But in the fall of 2001, as part of
Nigeria’s effort to increase research collaborations in
biotechnology with research institutes abroad, Dr.
Turner T. Isoun, a senior member of Nigeria’s Federal
Ministry of Science and Technology, led a delegation to
R u t g e r sU n i v e r s i t yf o rac o n f e r e n c et oe x p l o r eo p p o r t u -
nities for research collaborations [28]. It was at this
meeting that members of the Nigerian delegation met
Dr. Ramesh Pandey, CEO of US-based Xechem Interna-
tional and an experienced bio-entrepreneur with exper-
tise in pharmaceutical manufacturing. Dr. Pandey’s
affiliation with Rutgers University dated back to the
1980s when Dr. Pandey was a Visiting Professor at the
Waksman Institute of Microbiology; at the time of the
delegation’s visit, Dr. Pandey’s firm was collaborating
with the university on various research projects [28]. Dr.
Isoun offered Dr. Pandey an invitation to Nigeria to
explore possible collaboration in biotechnology.
After visiting Nigeria and meeting with officials at
NIPRD, Dr Pandey became aware of Niprisan’s potential
to treat sickle-cell anemia, and decided to take the
opportunity to lead Niprisan’s commercialization pro-
gram. On July 18
th 2002, Xechem was granted an exclu-
sive license to commercialize Niprisan for the treatment
of sickle cell anemia. In exchange, NIPRD reportedly
received a 7.5% royalty rate of gross sales, and an up-
front cash payment of $115,000 [21].
Commercial strategy
According to our interviews with Dr. Pandey and mem-
bers of the NIPRD, Niprisan was estimated to have a
market potential of tens of millions of dollars annually
in Nigeria alone, and Xechem reportedly intended to
sell a month’s supply of the drug for $20-$25 USD.
The decision to produce Niprisan locally was a stipu-
lation laid out in the licensing agreement between
Xechem and NIPRD. Given the sales potential, Nigeria’s
comparative advantage in raw materials, and land for
the manufacturing facility provided free of cost by the
Nigerian government, the advantages of being located in
Nigeria outweighed concerns over manufacturing cap-
abilities, according to Dr. Pandey and other sources [21].
Our interviews with Dr. Pandey indicated that
Xechem intended to make Niprisan available in the Uni-
ted States by leveraging the orphan drug designation
program offered by the US Food and Drug Administra-
tion. This designation was sought by Dr. Pandey, who
submitted an application after learning that sickle cell
anemia is listed as an orphan drug disease in the United
States – one from which a percentage of African-Ameri-
cans suffer, who would be potential users of this treat-
ment. Orphan drug status was granted in 2003 and
brought Xechem advantages including waiving of regula-
tory fees, additional funding, and an increase in investor
confidence [29-31].
Launch – and crash
In July of 2006, the National Agency for Food and Drug
Administration and Control approved Niprisan for sale
in Nigeria. In a strong display of government support,
the Nigerian President Olusegun Obasanjo was present
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Niprisan) in Nigeria [28].
However, revenues generated from small-scale produc-
tion were disappointing: the drug generated revenue
totaling $197,000 as of December 31, 2006 [30]. Accord-
ing to our interviews, sufficient demand for the product
was evident, but production bottlenecks including raw
material supply and scaling up manufacturing began to
arise. Further, according to Xechem International’s 2006
annual report, its operating losses as of December 31,
2005 and 2006 were in excess of $4 million [30]. Con-
cerns rose over the financial and operational stability of
Xechem, despite Xechem securing nearly $9 million in
loan commitments from US and Nigerian banks to fund
the construction of the manufacturing facility in Nigeria
[32-35].
In December 2006, Xechem International announced
the appointment of Mr. Iretiolu Oniyide, a Nigerian
with a banking background, to handle the day-to-day
operations of Xechem in Nigeria and to carry forward
the commercialization of Nicosan in Nigeria [30-35]. In
July of 2007, Xechem announced a plan to reduce costs,
which included closing down their US operations and
increasing its operational capacity in Nigeria [30-35]. In
addition to new cost cutting measures, Dr. Robert Swift
became the chief executive officer of Xechem Interna-
tional, replacing Dr. Pandey [30-35]. Despite the finan-
cial and structural changes, Xechem International filed
for bankruptcy in the United States in late 2008, and in
early 2009 the Nigerian government revoked the license
for Niprisan [34].
Lessons learned
Niprisan’s commercial demise has been attributed to
multiple factors, including a lack of cash flow, manage-
ment missteps, challenges in manufacturing and product
development, and a timeline to large-scale manufactur-
ing that was longer and more difficult than anticipated.
We examine five key lessons that can be drawn from
the case of Niprisan to illustrate how policy-makers
might support entrepreneurs and domestic innovation
in Nigeria, and more broadly in sub-Saharan Africa and
the developing world.
Support business-friendly environments
According to the World Bank, Nigeria ranks poorly
when compared to OECD countries in parameters that
include dealing with construction permits, enforcing
contracts, starting a business, registering property, and
trading across borders [36]. Some of these issues were
evident in the development of Niprisan, as Xechem
experienced delays in securing construction permits and
importing equipment. As Dr. Pandey recalls, “one of the
biggest hurdles in operating Xechem Nigeria was the
difficulty in getting day-to-day activities done. It is very
difficult in Nigeria.” To improve the local business
environment, especially when firms are working with
international partners, governments should aim to
reduce the time firms spend getting approval for ser-
vices that have a direct impact on business performance,
i.e. importing/exporting, customs tariffs, and land
permits.
Broker benefit-sharing agreements with traditional medical
healers
To increase knowledge sharing between traditional
medical healers and conventional scientists, and poten-
tially tap into a new source of drug products, NIPRD
implemented benefit-sharing agreements that allowed a
traditional medical healer to participate in the profits
of any drug originating from their recipe. Such agree-
ments allowed NIPRD to foster relationships with tra-
ditional medical healers across Nigeria, in an effort to
identify promising treatments for further development.
According to Dr. Wambebe, one of the aims of the
benefit-sharing agreements was to engage the stake-
holders as much as possible in the process, ensuring
that everyone was both motivated and vested in the
success of the product. In the case of Niprisan, Rever-
end Ogunyale was involved in the development work
of Niprisan via a staff position at NIPRD, which also
led to a publication [27].
Prior to the establishment of NIPRD, many traditional
remedies used by local healers went undocumented. In
the case of Niprisan, NIPRD relied on Reverend Ogu-
nyale for his knowledge of the plants and herbs used in
the formulation of Niprisan. To be successful in sup-
porting domestic pharmaceutical drug development, pol-
icy-makers should consider benefit-sharing agreements
as a model for sourcing new medicines, by bringing
together conventional scientists with traditional medical
healers in a fair and equitable manner. (For another
institution that has successfully implemented benefit-
s h a r i n gi nA f r i c a ,s e et h ep a p e ro nI M R Ai nt h i sB M C
series.)
Expand incentives for local innovation
Nigeria, like many developing countries, has limited
capacity to provide broad health care coverage, includ-
ing reimbursement of pharmaceuticals. While NIPRD’s
partner Xechem forecasted millions of dollars in reven-
ues, it may not have fully considered the implications of
the fact that the majority of purchases would be out-of-
pocket expenses for the consumer.
According to the directors at NIPRD, “many of the
patients who were on Niprisan could no longer afford
to continue taking the medication.” Prior to commercial
production of Niprisan by Xechem, the price of the
drug in Nigeria was reportedly set at $4 USD a month.
After licensing Niprisan to Xechem, the price reportedly
increased to $20-25 USD per month, which included
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kept affordable and incentives for local innovation
remain, governments should continue to seek policies
that address broad health coverage in Nigeria, in addi-
tion to expanding programs aimed to subsidize the cost
of research and development. Without proper incentives
to address price and cost of development, good alterna-
tive treatments developed from indigenous sources may
be out of reach for the majority of the population.
Improve standardization and quality control
Despite being approved by the National Agency for
Food and Drug Administration and Control in Nigeria,
Xechem experienced quality control issues. According
to Xechem’s 2006 annual report, securing and sourcing
the correct raw materials for the preparation proved to
be challenging: “there is a lack of data to document the
influence of raw materials (i.e. plant material quality,
age, time of harvest, location, soil quality, preparation,
handling, etc…) on the production of NICOSAN”
(Niprisan) [31]. Xechem acknowledged the difficulty in
establishing a consistent formulation of the drug, an
issue that was raised by the US Food and Drug Admin-
istration and Dr. Asakura.
Establishing quality control is the most important bar-
rier to success, says Dr. Inyang:
You should employ people that are trained and qua-
lified in botanical research. They need to know
exactly what they are doing, because there is a lot of
variability in plants and herbs, and accurately sour-
cing the raw materials is critical for consistency….
you should be able to standardize the product, that’s
the key word – standardize. Without that, it will
undermine the value of traditional medicines,
because any variation will affect the potency.
Despite Dr. Pandey’s expertise in pharmaceutical
development, securing personnel to handle manufactur-
ing proved to be difficult. One means to reduce produc-
tion bottlenecks for firms looking to build
manufacturing capacity in Nigeria might be to create
applied training programs and internships in pharma-
ceutical manufacturing and quality control. The impor-
tance of training and on-the-job experience is further
echoed by Dr. Inyang, who says “If you don’th a v et h e
money to buy the equipment, do the quality control,
and train your workforce, then you are going to run
into trouble.”
Foster partnerships to fill gaps in knowledge and technical
expertise
Local production does provide advantages, but govern-
ment agencies should also consider the challenges of the
local environment and how it may affect collaborations.
The partnering processes that led to the selection of
Xechem as the commercial partner provides lessons for
government agencies wishing to support local innova-
tion, and for drug developers who need to manage the
partnership. Government agencies must balance the
potential economic gains of establishing a local pharma-
ceutical industry with the realities of the necessary skills
and resources needed to support drug development in a
resource-constrained environment.
NIPRD is a research institute focused on studying tra-
ditional herbal medicines. Recognizing the importance
of having experienced collaborators with expertise in
sickle cell anemia and drug development, NIPRD opted
to collaborate with Children’s Hospital of Philadelphia
and Dr. Pandey, respectively. Each of these collabora-
tions contributed to reaching important milestones in
the development of Niprisan, with the Children’s Hospi-
tal of Philadelphia conducting animal studies confirming
the potential anti-sickling activity of Niprisan, and Dr.
Pandey being primarily responsible for handling the
manufacturing aspects of Niprisan.
For NIPRD, “a kind of multi-disciplinary collaboration
is needed throughout the research and development
process” says Dr. Wambebe. Multi-disciplinary colla-
borations, such as the partnerships with Rutgers Univer-
sity and Children’s Hospital of Philadelphia, will help
scientists and entrepreneurs in countries such as Nigeria
to address technological or learning gaps that would
otherwise derail a drug development program.
Once a partnership is made, it must also be managed.
Risks need to be understood and financial and manage-
rial due diligence done by all partners. While every part-
nership is based on trust, clear milestones along with
checks and balances may highlight problems early and
increase the probability of success.
Engage skilled entrepreneurial leaders
According to our interviews with members of NIPRD,
t h el a c ko fb i o - e n t r e p r e n e u rs willing and able to enter
high-risk capital-intensive biotechnology ventures is a
problem in Nigeria. Despite this, the role of Drs. Wam-
bebe, Inyang, and Pandey along with the team at NIPRD
illuminates an important resource in cultivating South-
ern innovation: leadership.
In our interviews with Dr. Wambebe, he said “the
most important thing I learned from this experience is
the need for a champion to lead the process and make
it happen – someone who can manage the partnerships,
recruit talented professionals, approach government for
funding, and handle the missteps and breakthroughs
that go along with early stage drug development.”
Dr. Wambebe lobbied the Nigerian government for
funds needed to conduct the early development work
and pilot clinical studies of Niprisan, and utilized fund-
ing sources such as the United Nations Development
Program to upgrade the NIPRD facilities.
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significant milestones for Niprisan. He raised financing
commitments from US and Nigerian governments,
negotiated a land deal, constructed a pilot manufactur-
ing facility capable of producing smaller quantities of
Niprisan, and spearheaded the granting of orphan drug
status for Niprisan.
Bio-entrepreneurs in resource-constrained environ-
ments may need to balance technical and business
responsibilities, and as Dr. Wambebe terms it act as the
“internal champion.” Because of the challenging environ-
ment, firms need to find strong leadership that can hold
dual scientific and business roles. Policy-makers should
likewise be mindful of the importance of leadership to
mitigate the risk of pitfalls; project management and sta-
keholder engagement are also important. Additional
efforts to provide business and leadership training are
warranted, whether through educational programs, on-
the job training, or mentorship linkages with experi-
enced professionals domestically or internationally.
Summary
One of the key facts to emphasize about Niprisan is that
it represents a novel drug for sickle-cell anemia, which
is a serious problem in both Africa and the United
States. Thus, the stakes are high. Although the first
commercialization attempt of Niprisan did not succeed
in making the drug widely available, the drug develop-
ment process up to this stage embodied a number of
significant achievements. As of this writing, NIPRD is
considering options for another commercial partner to
take the drug forward.
Despite these challenges, countries in sub-Saharan
Africa have previously participated in the development of
drugs from traditional medicines, illustrated by the isola-
tion of vincristine from Catharanthus roseus (an indigen-
ous plant to Madagascar used as an anti-cancer agent
[37]) and the use of Harpagophytum procumbens (Devil’s
Claw) to treat rheumatoid arthritis and inflammation
[12]. There are plans for more systematic drug develop-
ment support through initiatives such as the African Net-
work for Drugs and Diagnostics Innovation (ANDI) [38].
To effectively capitalize on the knowledge of tradi-
tional medical healers and researchers alike, future inno-
vation efforts need to incorporate broader actions aimed
at providing incentives for the private sector and entre-
preneurs, improving regulatory capacity, facilitating
international partnerships for technology transfer, and
brokering benefit sharing agreements between tradi-
tional medical healers and conventional scientists. Risks
of the commercialization process also need to be under-
stood by all partners, and financial and managerial due
diligence ensured.
Building the capacity to produce novel and affordable
medicines for local health problems may stimulate eco-
nomic development, decrease dependency on interna-
tional donor programs, and contribute to improving
global health. Looking forward, sharing findings and les-
sons from cases such as Niprisan will help remove bar-
riers on the road to commercialization in Africa. With
more experience and support, future drug development
efforts in Africa may increase their chances of success.
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